ArticleInternational journal of clinical oncology2021

Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate.

Masashi Kato et al.PubMed ↗Publisher ↗

No numbers read from the abstract.